Jane Liang

1.6k total citations
23 papers, 1.2k citations indexed

About

Jane Liang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Internal Medicine. According to data from OpenAlex, Jane Liang has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 9 papers in Internal Medicine. Recurrent topics in Jane Liang's work include Lung Cancer Treatments and Mutations (10 papers), Venous Thromboembolism Diagnosis and Management (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). Jane Liang is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Venous Thromboembolism Diagnosis and Management (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). Jane Liang collaborates with scholars based in United States, Canada and Spain. Jane Liang's co-authors include Russell D. Hull, Joseph O’Connell, Ian W. Taylor, Stephen P. Letrent, Pasi A. Jänne, Suresh S. Ramalingam, Michael Boyer, D. Ross Camidge, Alicyn Campbell and Paul D. Stein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Jane Liang

22 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Liang United States 14 726 629 320 303 207 23 1.2k
Elizabeth Dudnik Israel 19 817 1.1× 717 1.1× 221 0.7× 130 0.4× 74 0.4× 69 1.2k
Lothar Müller Germany 13 424 0.6× 269 0.4× 163 0.5× 197 0.7× 99 0.5× 71 850
Matteo Brighenti Italy 12 628 0.9× 316 0.5× 182 0.6× 66 0.2× 97 0.5× 38 869
L. Falchero France 18 673 0.9× 1.0k 1.6× 172 0.5× 52 0.2× 127 0.6× 71 1.4k
A.K. Kakkar United Kingdom 13 273 0.4× 120 0.2× 269 0.8× 508 1.7× 135 0.7× 28 1.0k
Thomas J. Semrad United States 15 395 0.5× 237 0.4× 257 0.8× 135 0.4× 122 0.6× 51 890
Baktiar Hasan Belgium 21 658 0.9× 1.4k 2.2× 156 0.5× 50 0.2× 337 1.6× 45 1.8k
C.J. Cornell United States 11 175 0.2× 119 0.2× 233 0.7× 242 0.8× 63 0.3× 19 842
Laura Visa Spain 15 662 0.9× 417 0.7× 180 0.6× 49 0.2× 262 1.3× 37 1.0k
Roberto Moretto Italy 15 623 0.9× 207 0.3× 124 0.4× 110 0.4× 178 0.9× 69 872

Countries citing papers authored by Jane Liang

Since Specialization
Citations

This map shows the geographic impact of Jane Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Liang more than expected).

Fields of papers citing papers by Jane Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Liang. The network helps show where Jane Liang may publish in the future.

Co-authorship network of co-authors of Jane Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Liang. A scholar is included among the top collaborators of Jane Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Liang. Jane Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Jenny, Cathy Wang, Jane Liang, et al.. (2022). Evaluation of Lynch syndrome risk models in a multicenter diverse population.. Journal of Clinical Oncology. 40(16_suppl). 10597–10597.
2.
Trpkov, Cvetan, Jane Liang, Danielle A. Southern, et al.. (2021). VISUALLY ESTIMATED CORONARY ARTERY CALCIUM SCORE IMPROVES SPECT-MPI RISK STRATIFICATION. Journal of the American College of Cardiology. 77(18). 1351–1351. 2 indexed citations
3.
Keyvanjah, Kiana, Blaire Cooke, David E. Martin, et al.. (2019). Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. Cancer Chemotherapy and Pharmacology. 84(5). 1125–1132. 2 indexed citations
4.
Ramalingam, Suresh S., Pasi A. Jänne, Tony Mok, et al.. (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 15(12). 1369–1378. 111 indexed citations
5.
6.
7.
Liang, Jane, David Bergqvist, Roger D. Yusen, & Russell D. Hull. (2013). Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. Thrombosis and Haemostasis. 112(2). 199–212. 6 indexed citations
8.
Hull, Russell D., et al.. (2013). Venous Thromboembolism in Elderly High-Risk Medical Patients. Clinical and Applied Thrombosis/Hemostasis. 19(4). 357–362. 39 indexed citations
9.
10.
Hull, Russell D., et al.. (2013). Effect of Long-Term LMWH on Post-thrombotic Syndrome in Patients With Iliac/Noniliac Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis. 19(5). 476–481. 14 indexed citations
11.
Boyer, Michael, Pasi A. Jänne, Tony Mok, et al.. (2012). ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.. Journal of Clinical Oncology. 30(15_suppl). TPS7615–TPS7615. 13 indexed citations
12.
Ramalingam, Suresh S., Fiona Blackhall, Maciej Krzakowski, et al.. (2012). Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(27). 3337–3344. 211 indexed citations
13.
Jänne, Pasi A., David S. Boss, D. Ross Camidge, et al.. (2011). Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 17(5). 1131–1139. 149 indexed citations
14.
Hull, Russell D., et al.. (2011). Long-term Low-Molecular-Weight Heparin and the Post-Thrombotic Syndrome: A Systematic Review. The American Journal of Medicine. 124(8). 756–765. 75 indexed citations
15.
Matta, Fadi, et al.. (2010). Venous Compression for Prevention of Postthrombotic Syndrome: A Meta-analysis. The American Journal of Medicine. 123(8). 735–740. 52 indexed citations
16.
Kirkwood, John M., Paul Lorigan, Peter Hersey, et al.. (2010). Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma. Clinical Cancer Research. 16(3). 1042–1048. 172 indexed citations
17.
Boyer, Michael, Fiona Blackhall, K. Park, et al.. (2010). Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).. Journal of Clinical Oncology. 28(18_suppl). LBA7523–LBA7523. 43 indexed citations
18.
Hull, Russell D., Graham F. Pineo, Rollin Brant, et al.. (2009). Home Therapy of Venous Thrombosis with Long-term LMWH versus Usual Care: Patient Satisfaction and Post-thrombotic Syndrome. The American Journal of Medicine. 122(8). 762–769.e3. 70 indexed citations
19.
Jänne, Pasi A., Karen L. Reckamp, Marianna Koczywas, et al.. (2009). Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. Journal of Clinical Oncology. 27(15_suppl). 8063–8063. 36 indexed citations
20.
Stein, Paul D., Russell D. Hull, Fadi Matta, Abdo Y. Yaekoub, & Jane Liang. (2009). Incidence of Thrombocytopenia in Hospitalized Patients with Venous Thromboembolism. The American Journal of Medicine. 122(10). 919–930. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Dudnik Breakdown of academic impact, for papers by Lothar Müller Breakdown of academic impact, for papers by Matteo Brighenti Breakdown of academic impact, for papers by L. Falchero Breakdown of academic impact, for papers by A.K. Kakkar Breakdown of academic impact, for papers by Thomas J. Semrad Breakdown of academic impact, for papers by Baktiar Hasan Breakdown of academic impact, for papers by C.J. Cornell Breakdown of academic impact, for papers by Laura Visa Breakdown of academic impact, for papers by Roberto Moretto
Rankless by CCL
2026